Dose rounding of trastuzumab deruxtecan in chinese patients: cost savings and safety outcomes in real-world study - Top-Institutions - MDSpire

Dose rounding of trastuzumab deruxtecan in chinese patients: cost savings and safety outcomes in real-world study

  • By

  • Haochun Tang

  • Ziying Li

  • Ziyuan Zhou

  • Lingzhi Ren

  • Chengsheng Xie

  • Jun Meng

  • Guohui Li

  • June 15, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    National Cancer Center
    National Cancer Center

    Beijing, Beijing

    Key Differentiators

    • Oncology

  • #2

    National Clinical Research Center for Cancer
    National Clinical Research Center for Cancer

    Beijing, Beijing

    Key Differentiators

    • Oncology

  • #3

    Shenzhen Hospital
    Shenzhen Hospital

    Shenzhen, Guangdong

    Key Differentiators

    • Oncology

  • #4

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #5

    Jonsson Comprehensive Cancer Center
    Jonsson Comprehensive Cancer Center

    Los Angeles, California

    Key Differentiators

    • Oncology

Original Source(s)

Dose rounding of trastuzumab deruxtecan in chinese patients: cost savings and safety outcomes in real-world study

  • by Haochun Tang, Ziying Li, Ziyuan Zhou, Lingzhi Ren, Chengsheng Xie, Jun Meng, Guohui Li

  • June 15, 2026

Related Content

Early identification of neoadjuvant therapy non-response via multimodal immune-imaging biomarkers in breast cancer

Editorial: Challenges and strategies in the management of ER/PgR Low-expression breast cancer: exploring fundamentals, clinical insights, and treatment approaches

Intensified MR-guided pulsed adaptive cancer treatment- a potential new treatment option for large(>5cm) central non-small cell lung cancer, a case report